Literature DB >> 9579583

Ecotropic C-type retrovirus of B16 melanoma and malignant transformation of normal melanocytes.

M Li1, F Xu, J Muller, V J Hearing, E Gorelik.   

Abstract

We reported previously that B16,JB/RH and JB/MS melanomas of C57BL/6 mice express the common melanoma-associated antigen (MAA) recognized by MM2-9B6 monoclonal antibody (MAb). This MAA is encoded by the env gene of an ecotropic MuLV-type retrovirus that somatically emerged in melanomas of C57BL/6 mice. The potential role of this melanoma-associated retrovirus (MelARV) in melanoma formation remains unknown and has not been previously investigated. To test this, normal melanocyte lines (melan-a and C57M) of C57BL/6 mice were infected with the MelARV produced by B16BL6 melanoma. Infection of these melanocytes with the MelARV was associated with the appearance of the MAA recognized by MM2-9B6 MAb. Most of the infected melanocyte sublines were able to grow only in the presence of 12-O-tetradecanoylphorbol-13-acetate (TPA). Two infected melanocyte sublines showed morphological changes, were able to grow in the absence of TPA and, after inoculation into C57BL/6 mice, produced rapidly growing, highly pigmented tumors. These new melanomas, derived from the MelARV-infected melan-a and C57M melanocytes, were termed Meli-A1 and Meli-BL, respectively. Southern blot analysis of EcoRI- and HindIII-digested DNAs from these melanomas showed several retroviral insertion sites. One copy of MeIARV was found to be inserted at the end of the 6th leucine domain of the c-maf proto-oncogene, which encodes a basic region/leucine zipper transcription factor related to the AP-1 family that is able to form homodimers or heterodimers with Fos and Jun transcription factors. Our data indicate that c-maf is a common insertion site of MelARV in BL6, Meli-A1 and Meli-BL melanomas, whereas no such insertion site was found in the melanocytes infected with MelARV but not malignantly transformed. Thus, our data imply that the ecotropic MelARV that somatically emerged in B16 and other melanomas of C57BL/6 mice may play a role in malignant transformation.

Entities:  

Mesh:

Year:  1998        PMID: 9579583     DOI: 10.1002/(sici)1097-0215(19980504)76:3<430::aid-ijc23>3.0.co;2-d

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Mouse model for pre-clinical study of human cancer immunotherapy.

Authors:  Zhiya Ya; Yared Hailemichael; Willem Overwijk; Nicholas P Restifo
Journal:  Curr Protoc Immunol       Date:  2015-02-02

2.  B16 as a mouse model for human melanoma.

Authors:  W W Overwijk; N P Restifo
Journal:  Curr Protoc Immunol       Date:  2001-05

Review 3.  Infection barriers to successful xenotransplantation focusing on porcine endogenous retroviruses.

Authors:  Joachim Denner; Ralf R Tönjes
Journal:  Clin Microbiol Rev       Date:  2012-04       Impact factor: 26.132

4.  Sequence and insertion sites of murine melanoma-associated retrovirus.

Authors:  M Li; X Huang; Z Zhu; E Gorelik
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

5.  Identification of Highly Cross-Reactive Mimotopes for a Public T Cell Response in Murine Melanoma.

Authors:  Beth E Grace; Coralie M Backlund; Duncan M Morgan; Byong H Kang; Nishant K Singh; Brooke D Huisman; C Garrett Rappazzo; Kelly D Moynihan; Laura Maiorino; Connor S Dobson; Taeyoon Kyung; Khloe S Gordon; Patrick V Holec; Overbeck C Takou Mbah; Daniel Garafola; Shengwei Wu; J Christopher Love; K Dane Wittrup; Darrell J Irvine; Michael E Birnbaum
Journal:  Front Immunol       Date:  2022-06-23       Impact factor: 8.786

Review 6.  The role of transcription factor Nrf2 in skin cells metabolism.

Authors:  Agnieszka Gęgotek; Elżbieta Skrzydlewska
Journal:  Arch Dermatol Res       Date:  2015-02-24       Impact factor: 3.017

7.  Restoration of Endogenous Retrovirus Infectivity Impacts Mouse Cancer Models.

Authors:  Eleonora Ottina; Prisca Levy; Urszula Eksmond; Julia Merkenschlager; George R Young; Juliette Roels; Jonathan P Stoye; Thomas Tüting; Dinis P Calado; George Kassiotis
Journal:  Cancer Immunol Res       Date:  2018-08-24       Impact factor: 11.151

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.